P

PhaseBio Pharmaceuticals, Inc.

32 employees

PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.

Basic info

Industry

biotechnology research

Sectors

Elastin-like polypeptide biopolymer
Heart failure
Medical Device
Biotechnology
slow absorption
Pharmaceutical
Pulmonary Arterial Hypertension
Ticagrelor reversal agent
Vasoactive Intestinal Peptide
DMD cardiomyopathy
Orphan diseases
cardiopulmonary disorders
Medical
phase transition
improved biotherapeutics

Date founded

2002

Funding rounds raised

Total raised

$120M

from 10 investors over 10 rounds

P

PhaseBio Pharmaceuticals, Inc. raised $120M on January 13, 2020

Investors: SFJ Pharmaceuticals, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $34M on September 5, 2018

Investors: Syno Capital, Fletcher Spaght, Inc. and Mountain Group Partners

P

PhaseBio Pharmaceuticals, Inc. raised $2.8M on February 27, 2018

Investors: National Institutes of Health

P

PhaseBio Pharmaceuticals, Inc. raised $40M on March 12, 2015

Investors: Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $23M on June 5, 2012

Investors: Astellas Venture Capital L.L.C. and Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $25M on January 7, 2010

Investors: Fletcher Spaght, Inc.

P

PhaseBio Pharmaceuticals, Inc. raised $6.6M on October 24, 2007

Investors: Fletcher Spaght, Inc.

FAQ